Clinical trialNCT00594880CompletedPhase 2Interventional

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

SponsorThe Wistar InstituteEnrollment23HIV Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180 ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART (antiretroviral therapy) interruption in HIV positive, ART-suppressed subjects (viral load \<50 copies/ml) as determined by observing the percentages of viral load measurements \<400 copies/ml between the two arms over a 24-week period, corresponding to the Pegasys monotherapy period (exclusive of dual ART/Pegasys 5-week period). Primary analysis will be an "intent to treat" analysis and will address the hypothesis that two different doses of Peg-INF-α-2A (90 and 180 ug/week) will be similarly effective at inhibiting viral replication.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jay Kostman, MD
Penn-Presbyterian Medical Center
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Jacobson, MD
Drexel University College of Medicine
Principal Investigator
clinicaltrials.gov ↗
Karam Mounzer, MD
Jonathan Lax Immune Disorders Clinic- Philadelphia FIGHT
Principal Investigator
clinicaltrials.gov ↗
Luis Montaner, DVM, PhD
The Wistar Institute
Study Chair
clinicaltrials.gov ↗
Pablo Tebas, MD
University of Pennsylvania
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Drexel University College of Medicine
Philadelphia, Pennsylvania, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Jonathan Lax Immune Disorders Clinic
Philadelphia, Pennsylvania, United States
Penn-Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
the Wistar Institute
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Peginterferon alfa-2a →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2008
Primary completion: 30 Nov 2010
Completion: 31 May 2011
Last update posted: 10 Feb 2015
Registered enrollment: 23
Registry id: NCT00594880

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.